Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability

View ORCID ProfileSabrina E. Racine-Brzostek, Mohsen Karbaschi, Christian Gaebler, P.J. Klasse, Jim Yee, Marina Caskey, He S. Yang, Ying Hao, Amy Chadburn, Yuanyuan Shi, Robert Zuk, Michel C. Nussenzweig, Melissa M. Cushing, Zhen Zhao
doi: https://doi.org/10.1101/2021.02.03.21251089
Sabrina E. Racine-Brzostek
1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
2NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sabrina E. Racine-Brzostek
Mohsen Karbaschi
3ET HealthCare, Palo Alto, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Gaebler
4Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.J. Klasse
5Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim Yee
1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
2NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina Caskey
4Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
He S. Yang
1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
2NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Hao
1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
6School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Chadburn
1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
2NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuanyuan Shi
6School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China
7Department of Biomedical Engineering, Shenzhen Research Institute, Beijing University of Chinese Medicine, Shenzhen, Guangdong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Zuk
3ET HealthCare, Palo Alto, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel C. Nussenzweig
4Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
8Howard Hughes Medical Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa M. Cushing
1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
2NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhen Zhao
1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
2NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhz9010@med.cornell.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background There is a concern that low initial SARS-CoV-2 antibody titers in individuals may drop to undetectable levels within months after infection. Although this may raise concerns over long term immunity, both the antibody levels and avidity of the antibody-antigen interaction should be examined to understand the quality of the antibody response.

Methods A testing-on-a-probe “plus” panel (TOP-Plus) was developed, which included a newly developed avidity assay built into the previously described SARS-CoV-2 TOP assays that measured total antibody (TAb), surrogate neutralizing antibody (SNAb), IgM and IgG on a versatile biosensor platform. TAb and SNAb levels were compared with avidity in previously infected individuals at 1.3 and 6.2 months post-infection in paired samples from 80 COVID-19 patients.

Results The newly designed avidity assay in this TOP panel correlated well with a reference Bio-Layer Interferometry avidity assay (R=0.88). The imprecision of the TOP avidity assay was less than 9%. Although TAb and neutralization activity (by SNAb) decreased between 1.3 and 6.2 months post infection, the antibody avidity increased significantly (P < 0.0001).

Conclusion This highly precise and versatile TOP-Plus panel with the ability to measure SARS-CoV-2 TAb, SNAb, IgG and IgM antibody levels and avidity of individual sera on one sensor can become a valuable asset in monitoring not only SARS-CoV-2-infected patients, but also the status of individuals’ COVID-19 vaccination response.

Competing Interest Statement

Z.Z. received seed instruments and sponsored travel from ET Healthcare. Y.H. was funded by China Scholarship Council. The rest of the authors declare that they have no conflict of interests with the present work

Funding Statement

This work was supported by a COVID-19 research grant from Weill Cornell Medicine (M.C.), Weill Cornell Medicine Translational Research Program of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine (grant number COVID3376; Z.Z.). NIH grant R01 AI36082 (P.J.K.) and NIH grant P01-AI138398-S1 and 2U19AI111825 (M.C.N.). C.G. was supported by the Robert S. Wennett Post-Doctoral Fellowship, in part by the National Center for Advancing Translational Sciences (National Institutes of Health Clinical and Translational Science Award program, grant UL1 TR001866), and by the Shapiro-Silverberg Fund for the Advancement of Translational Research. M.C.N. is a Howard Hughes Medical Institute Investigators.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by Rockefeller University (IRB# DRO-1006) and determined to meet exemption requirements by Weill Cornell Medicine Institutional Review Board.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

An anonymized dataset and data analysis code may be available upon application to the corresponding author and institutional review as per Weill Cornell Medicine data sharing policies

  • Abbreviation list

    COVID-19
    Corona Virus Disease-2019
    SARS-CoV-2
    Severe Acute Respiratory Syndrome Coronavirus 2
    RT-PCR
    real-time polymerase chain reaction
    RBD
    receptor-binding domain
    TOP
    testing-on-a-probe
    HPLC
    high performance liquid chromatography
    SRID
    single radial immunodiffusion
    SPR
    Surface Plasmon Resonance
    BLI
    Bio-Layer Interferometry
    RFU
    relative fluorescence unit
    dR
    relative dissociation rate
    TAb
    total antibody
    SNAb
    surrogate neutralizing antibody
    ELISA
    Enzyme-linked immunosorbent assays
    PRNT
    plaque reduction neutralization test
    PsV
    pseudo virus neutralization test
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted February 08, 2021.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability
    Sabrina E. Racine-Brzostek, Mohsen Karbaschi, Christian Gaebler, P.J. Klasse, Jim Yee, Marina Caskey, He S. Yang, Ying Hao, Amy Chadburn, Yuanyuan Shi, Robert Zuk, Michel C. Nussenzweig, Melissa M. Cushing, Zhen Zhao
    medRxiv 2021.02.03.21251089; doi: https://doi.org/10.1101/2021.02.03.21251089
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability
    Sabrina E. Racine-Brzostek, Mohsen Karbaschi, Christian Gaebler, P.J. Klasse, Jim Yee, Marina Caskey, He S. Yang, Ying Hao, Amy Chadburn, Yuanyuan Shi, Robert Zuk, Michel C. Nussenzweig, Melissa M. Cushing, Zhen Zhao
    medRxiv 2021.02.03.21251089; doi: https://doi.org/10.1101/2021.02.03.21251089

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Allergy and Immunology
    Subject Areas
    All Articles
    • Addiction Medicine (280)
    • Allergy and Immunology (579)
    • Anesthesia (139)
    • Cardiovascular Medicine (1947)
    • Dentistry and Oral Medicine (252)
    • Dermatology (184)
    • Emergency Medicine (333)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (699)
    • Epidemiology (11102)
    • Forensic Medicine (8)
    • Gastroenterology (624)
    • Genetic and Genomic Medicine (3168)
    • Geriatric Medicine (308)
    • Health Economics (561)
    • Health Informatics (2042)
    • Health Policy (863)
    • Health Systems and Quality Improvement (782)
    • Hematology (310)
    • HIV/AIDS (682)
    • Infectious Diseases (except HIV/AIDS) (12720)
    • Intensive Care and Critical Care Medicine (707)
    • Medical Education (317)
    • Medical Ethics (92)
    • Nephrology (334)
    • Neurology (2986)
    • Nursing (164)
    • Nutrition (463)
    • Obstetrics and Gynecology (589)
    • Occupational and Environmental Health (614)
    • Oncology (1552)
    • Ophthalmology (477)
    • Orthopedics (185)
    • Otolaryngology (266)
    • Pain Medicine (202)
    • Palliative Medicine (57)
    • Pathology (403)
    • Pediatrics (912)
    • Pharmacology and Therapeutics (381)
    • Primary Care Research (355)
    • Psychiatry and Clinical Psychology (2785)
    • Public and Global Health (5591)
    • Radiology and Imaging (1094)
    • Rehabilitation Medicine and Physical Therapy (635)
    • Respiratory Medicine (760)
    • Rheumatology (338)
    • Sexual and Reproductive Health (311)
    • Sports Medicine (289)
    • Surgery (343)
    • Toxicology (48)
    • Transplantation (159)
    • Urology (132)